The adverse event database will now collect patient age, weight, ethnicity and race, which aligns with recent FDA efforts to better track information on how medical products may affect people from different demographic groups.
People reporting device-related adverse events to the US Food and Drug Administration can now include more information about the affected patients, the agency announced today.
The Manufacturer and User Facility Device Experience (MAUDE), as well as the openFDA data endpoint, have been updated to include fields for patient age, weight, ethnicity and race
While MedTech Europe sharpens its focus on what the EU most urgently needs to advance the medtech market in four targeted measures, the European Commission has also unveiled four priorities for 2025.
The US Food and Drug Administration has announced new classifications for eight device types that reached market via the de novo process, with most of the newly classified products in the diagnostics sector.
The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.
Global investment in consumer healthtech increased by 9% year-over-year in 2024, totaling $4.5bn, with significant interest in mental health solutions, according to Galen Growth. While the first quarter of 2025 saw raised confidence and investments, the Trump administration’s new tariffs and sweeping changes to healthcare have introduced new uncertainties.
